The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Gu rin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report
Authors:
- 1 January 1994
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 35 (S1) , S65-S68
Abstract
The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin (BCG) for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 29 patients aged a median of 70 years between January of 1991 and May of 1993. The patients received intravesical instillation of 40 mg epirubicin immediately after transurethral resection (TUR) of the bladder cancer. At 1 week after TUR, 80 mg Tokyo-strain BCG was instilled into the bladder once a week for 6 weeks. Thereafter, the patients were followed by cystoscopy and urinary cytology at 3-month intervals until recurrence was detected. Of the 29 patients, 28 had no evidence of disease over a mean follow-up period of 20 months. The 1 case of recurrence occurred at 3 months after TUR and that patient died of cancer progression. The simple recurrence rate was 3.5% after therapy. According to the person-years method, the number of recurrent tumors per 100 patient-months was 0.17. The cumulative nonrecurrence rate determined for all cases was 96.5% at 30 months. Adverse reactions, including urinary frequency, urgency, and miction pain, among others, were observed in 27 patients (93%). Only 1 patient was withdrawn from the treatment because of severe bladder-irritation symptoms due to the BCG instillation. The intravesical chemoimmunotherapy with epirubicin and BCG seemed to be effective for prophylaxis of recurrence of superficial bladder cancer.Keywords
This publication has 12 references indexed in Scilit:
- Phase 1/2 Study of Intravesical Epirubicin in Patients with Carcinoma in Situ of the BladderJournal of Urology, 1991
- A Randomized Controlled Study of Intravesical α−2b-Interferon in Carcinoma in Situ of the BladderJournal of Urology, 1990
- Intravesical Bacillus Calmette‐Guérin Treatment for Superficial Bladder TumoursBritish Journal of Urology, 1989
- Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, 1985
- Intravesical Doxorubicin for Prophylaxis in the Management of Recurrent Superficial Bladder CarcinomaJournal of Urology, 1983
- Bladder cancerPostgraduate Medicine, 1983
- The Use of Intravesical Thio-Tepa in the Management of Non-invasive Carcinoma of the BladderJournal of Urology, 1981
- Factors Influencing the Recurrence Rate of Bladder CancerJournal of Urology, 1980
- Biopsy of Apparently Normal Urothelium in Patients with Bladder CarcinomaJournal of Urology, 1978
- Statistical methods for studying multiple primary malignant neoplasmsCancer, 1977